William Blair Starts Zealand Pharma A/S (ZEAL) at Market Perform

William Blair analyst Andy Hsieh initiates coverage on Zealand Pharma A/S (NASDAQ: ZEAL) with a Market Perform rating.

The analyst comments: "Zealand is advancing petrelintide, an amylin receptor agonist, which we believe could be differentiating in the obesity market. In addition to the potential for clinically meaningful weight loss, targeting amylin could enhance the gastrointestinal tolerability profile relative to the GLP-1 receptor class of drugs and improve body composition by limiting loss of lean body mass. Furthermore, we believe the mechanism is clinically validated by cagrilintide from Novo Nordisk. Beyond petrelintide, we believe that survodutide (being developed by partner Boehringer Ingelheim) will likely provide a source of more near-term revenue in obesity with metabolic dysfunction-associated steatohepatitis (MASH)."

For an analyst ratings summary and ratings history on Zealand Pharma A/S click here. For more ratings news on Zealand Pharma A/S click here.

Shares of Zealand Pharma A/S closed at $17.59 yesterday.

You May Also Be Interested In

• Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform
• Freedom Broker Starts Royal Caribbean Cruises (RCL) at Buy
• Bernstein SocGen Group Starts Cipher Mining (CIFR) at Outperform